2012 US Healthcare and Life Sciences Conference
Footage Now Available!


Following the success of the FT Global Pharmaceutical and Biotechnology Conference held in Europe for over 25 years, the Financial Times hosted the first US Healthcare and Life Sciences Conference on June 6, 2012 in New York.

Last year saw the passage into law of the milestone US healthcare legislation, and the beginnings of a sweeping overhaul of the US healthcare system. The implications for stakeholders across the entire healthcare continuum - for payers, for patients, and for providers, to include device manufacturers, life science companies and healthcare IT providers - are potentially profound. Yet the process of reform is fraught with political risk, with previously agreed exclusions such as government negotiations on pharma pricing, pay-for-delay, and drug reimportation now caught in the political crossfire. How can life science and healthcare companies manage for this uncertainty, and what lies ahead of US healthcare reform?

The FT US Healthcare and Life Sciences Conference brought together an international line-up of industry experts, government decision-makers and leading market commentators to review the shifting sands of the US healthcare industry, and assess the bottom-line impacts and implications for business and commercial strategies.

Topics of discussion included:

  • Delivering on the promise and potential of personalized medicine - what are the commercial models and strategies for the era of stratified medicine?
  • Biosimilars-coming of age?
  • A future based on value and outcomes - adjusting to the realities of Comparative Effectiveness Research (CER)
  • Social media and the age of healthcare consumerism
  • Remodelling the life sciences company for the 21st Century

     [Click here to view the program]


Andrew Jack
Pharmaceuticals Correspondent
Financial Times


Heather Bresch
Margaret Hamburg
US Food and Drug Administration
John Lechleiter
Chairman, President & CEO
Eli Lilly and Company
George Scangos
Chief Executive Officer
Biogen Idec

Jack Bailey
, Senior Vice President, Policy, Payers and Vaccines, GlaxoSmithKline
Kalipso Chalkidou, Director, NICE International
John Crowley, Chairman and Chief Executive Officer, Amicus Therapeutics 
Ronny Gal, Senior Analyst, Specialty Pharmaceuticals, Sanford C. Bernstein & Co
Nicholas Groombridge, Partner, Paul, Weiss, Rifkind, Wharton & Garrison LLP
David-Alexandre Gros, Chief Strategy Officer, Sanofi
R.T. (Terry) Hisey, Vice Chairman & US Life Sciences Leader, Deloitte LLP
Nancy Kelley, Founding Executive Director, NY Genome Center
Ameet Mallik, Global Head of Sandoz Biopharmaceuticals & Oncology Injectables, Sandoz
Michael McCallister, Chairman of the Board and Chief Executive Officer, Humana
Edward Michael, Executive Vice President, Diagnostics, Abbott Laboratories
David Nash, Dean, Jefferson School of Population Health, Thomas Jefferson University
Daniel Palestrant, Founder and CEO, Par8o
Andy Schmeltz, US Region President, Oncology Business Unit, Pfizer
Joe Selby, Executive Director, Patient Centered Outcomes Research Institute
Wes Wilkes, Executive Director of Global Strategy, InterbrandHealth
Marcus Wilson, President, HealthCore, a subsidiary of WellPoint

Delegate Inquiries:
Chrissy McNasby
+1 212-641-6369
Sponsorship Inquiries:
Tim Powell
+1 212-641-6170

Speaker Inquiries:
Angela Letinov